These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34324065)

  • 1. Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
    Yang Z; Yu R; Deng W; Wang W
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3279-3288. PubMed ID: 34324065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Association between chronic lung diseases and the risk of lung cancer in UK Biobank: observational and Mendelian randomization analyses].
    Zhang J; Ma ZM; Wang H; Fu YT; Ji C; Zhu M; Shen HB; Ma HX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Aug; 57(8):1147-1152. PubMed ID: 37574304
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration.
    Zhang D; Liu H; Zhao F; Guo P; Li J; Lu T; Li Z; Li S
    BMC Cancer; 2024 Apr; 24(1):453. PubMed ID: 38605291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
    Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
    Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
    Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
    Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
    PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causal association of rheumatoid arthritis with obstructive lung disease: Evidence from Mendelian randomization study.
    Cao Z; Li Q; Wu J; Li Y
    Heart Lung; 2023; 62():35-42. PubMed ID: 37302263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.
    Ritzmann F; Jungnickel C; Vella G; Kamyschnikow A; Herr C; Li D; Menger MM; Angenendt A; Hoth M; Lis A; Bals R; Beisswenger C
    Sci Rep; 2019 Jul; 9(1):10353. PubMed ID: 31316109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
    Zhang D; Huang J; Zhang C; Guan Y; Guo Q
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.
    Xu W; Cui J; Wu L; He C; Chen G
    Toxicol Appl Pharmacol; 2021 Sep; 426():115633. PubMed ID: 34166680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
    Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Evidence on the Association of Interleukin (IL)-1-Mediated Chronic Inflammation with Airflow Obstruction: A Mendelian Randomization Study.
    Yang Z; Schooling CM; Kwok MK
    COPD; 2021 Aug; 18(4):432-442. PubMed ID: 34348529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
    Rojkó L; Reiniger L; Téglási V; Fábián K; Pipek O; Vágvölgyi A; Agócs L; Fillinger J; Kajdácsi Z; Tímár J; Döme B; Szállási Z; Moldvay J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1219-1226. PubMed ID: 29675791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].
    Li M; Xu S; Fan H; Zhang H; Li Y; Li Y; Liu M; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):847-853. PubMed ID: 27978870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.